Amphastar Pharmaceuticals (AMPH) Common Equity (2013 - 2026)

Amphastar Pharmaceuticals' Common Equity history runs 14 years deep, the most recent figure standing at $773.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 2.94% year-over-year to $773.4 million in Q1 2026; TTM through Mar 2026 was $773.4 million, a 2.94% increase from a year earlier, with the FY2025 full-year figure at $788.8 million, up 7.72% from the prior year.
• Common Equity fell to $773.4 million in Q1 2026 per AMPH's latest filing, from $788.8 million in the prior quarter.
• Across five years, Common Equity topped out at $788.8 million in Q4 2025 and bottomed at $479.5 million in Q1 2022.
• The 5-year median for Common Equity is $672.4 million (2024), against an average of $651.7 million.
• Across the five-year window, Common Equity grew 22.56% in 2024 and gained 2.94% in 2026, its largest moves.
• Year by year, Common Equity stood at $528.7 million in 2022, then rose by 20.95% to $639.4 million in 2023, then gained by 14.53% to $732.3 million in 2024, then rose by 7.72% to $788.8 million in 2025, then declined by 1.95% to $773.4 million in 2026.
• Per Business Quant, the three latest AMPH Common Equity figures stand at $773.4 million (Q1 2026), $788.8 million (Q4 2025), and $776.7 million (Q3 2025).